<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03306134</url>
  </required_header>
  <id_info>
    <org_study_id>2017/05</org_study_id>
    <nct_id>NCT03306134</nct_id>
  </id_info>
  <brief_title>The Effect of Beta-blockers in Substance P Levels and the Swallowing Function</brief_title>
  <acronym>BETASP</acronym>
  <official_title>The Effect of Beta-blockers in Substance P Levels and the Swallowing Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Mataró</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Mataró</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A non-randomised, prospective study to assess the effects of beta-blockers on substance P
      levels and the swallowing function. The study is going to be carry out in the
      Gastrointestinal Physiology Laboratory of the Hospital de Mataró (Spain). All participants
      will be actively recruited from a Linked hospital and primary care database. We include two
      groups: the first group (group 1) are participants taking beta-blockers and the second group
      (group 2) are participants not-taking beta-blockers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Substance P levels</measure>
    <time_frame>1 year</time_frame>
    <description>In blood and saliva</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Beta Blockers</condition>
  <condition>Swallowing Disorder</condition>
  <condition>Substance P</condition>
  <arm_group>
    <arm_group_label>BETA-BLOCKERS</arm_group_label>
    <description>Patients taking beta-blockers with or without dysphagia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO BETA-BLOCKERS</arm_group_label>
    <description>Patients not taking beta-blockers with or without dysphagia</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dysphagia</intervention_name>
    <description>An overall assessment is going to be carry out by a multidisciplinary team during the visit.
Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire [4]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present.
All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)</description>
    <arm_group_label>BETA-BLOCKERS</arm_group_label>
    <arm_group_label>NO BETA-BLOCKERS</arm_group_label>
    <other_name>Diagnostic test</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All population.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients taking and not taking beta-blockers

        Exclusion Criteria:

          -  Participants with heat and neck or esophageal cancer

          -  Participants with stroke or neurological disease

          -  Participants with central nervous system disease

          -  Participants with concomitant treatment with Angiotensin converting enzyme inhibitors
             (ACEI), Angiotensin II receptor antagonists (ARA-II), Antipsychotics, Dopamine
             agonists, Capsaicine.

          -  Participants with severe clinical signs of aspiration, including oxygen desaturation
             ≥3%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Miarons</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mataró Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Miarons</last_name>
    <phone>0034600297227</phone>
    <email>mmiarons@csdm.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laia Rofes</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mataró Hospital</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Miarons</last_name>
      <phone>0034600297227</phone>
      <email>mmiarons@csdm.cat</email>
    </contact>
    <contact_backup>
      <last_name>Laia Rofes</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>October 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Mataró</investigator_affiliation>
    <investigator_full_name>Marta Miarons</investigator_full_name>
    <investigator_title>Clinical pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deglutition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Substance P</mesh_term>
    <mesh_term>Neurokinin A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

